Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Amgen Inc. (NASDAQ:AMGN)

Analysis of Long-term (Investment) Activity Ratios

Beginner level

Long-term Activity Ratios (Summary)

Amgen Inc., long-term (investment) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Net fixed asset turnover 4.96 4.51 4.54 4.37 4.41
Net fixed asset turnover (including operating lease, right-of-use asset) 4.58 4.11 4.54 4.37 4.41
Total asset turnover 0.39 0.37 0.34 0.27 0.28
Equity turnover 2.58 2.30 1.80 0.86 0.73

Based on: 10-K (filing date: 2021-02-09), 10-K (filing date: 2020-02-12), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Amgen Inc.’s net fixed asset turnover ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Amgen Inc.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Amgen Inc.’s total asset turnover ratio improved from 2018 to 2019 and from 2019 to 2020.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Amgen Inc.’s equity turnover ratio improved from 2018 to 2019 and from 2019 to 2020.

Net Fixed Asset Turnover

Amgen Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Product sales 24,240  22,204  22,533  21,795  21,892 
Property, plant and equipment, net 4,889  4,928  4,958  4,989  4,961 
Long-term Activity Ratio
Net fixed asset turnover1 4.96 4.51 4.54 4.37 4.41
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 8.73 11.23 11.36 10.07 9.85
Eli Lilly & Co. 2.83 2.83 2.75 2.59 2.57
Gilead Sciences Inc. 4.90 4.91 5.41 7.79 10.45
Illumina Inc. 3.51 3.99 3.10 2.96 3.36
Johnson & Johnson 4.40 4.65 4.79 4.50 4.52
Merck & Co. Inc. 2.67 3.11 3.18 3.23 3.31
Pfizer Inc. 3.01 3.71 4.01 3.79 3.97
Regeneron Pharmaceuticals Inc. 2.64 2.72 2.61 2.49 2.33
Thermo Fisher Scientific Inc. 5.45 5.38 5.85 5.17 7.09
Zoetis Inc. 3.03 3.23 3.51 3.70 3.54
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.95 4.18 4.32 4.20 4.40
Net Fixed Asset Turnover, Industry
Health Care 7.22 7.41 7.13 6.96 7.16

Based on: 10-K (filing date: 2021-02-09), 10-K (filing date: 2020-02-12), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 2020 Calculation
Net fixed asset turnover = Product sales ÷ Property, plant and equipment, net
= 24,240 ÷ 4,889 = 4.96

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Amgen Inc.’s net fixed asset turnover ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Amgen Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Product sales 24,240  22,204  22,533  21,795  21,892 
 
Property, plant and equipment, net 4,889  4,928  4,958  4,989  4,961 
Operating lease right-of-use (ROU) assets (located in Other assets) 408  469  —  —  — 
Property, plant and equipment, net (including operating lease, right-of-use asset) 5,297  5,397  4,958  4,989  4,961 
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 4.58 4.11 4.54 4.37 4.41
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 7.46 10.06 11.36 10.07 9.85
Eli Lilly & Co. 2.63 2.66 2.75 2.59 2.57
Gilead Sciences Inc. 4.34 4.28 5.41 7.79 10.45
Illumina Inc. 2.23 2.45 3.10 2.96 3.36
Johnson & Johnson 4.18 4.41 4.79 4.50 4.52
Merck & Co. Inc. 2.43 2.90 3.18 3.23 3.31
Pfizer Inc. 2.74 3.39 4.01 3.79 3.97
Regeneron Pharmaceuticals Inc. 2.62 2.70 2.61 2.49 2.33
Thermo Fisher Scientific Inc. 4.82 4.69 5.85 5.17 7.09
Zoetis Inc. 2.79 2.94 3.51 3.70 3.54
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.60 3.84 4.32 4.20 4.40
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 5.69 5.86 7.13 6.96 7.16

Based on: 10-K (filing date: 2021-02-09), 10-K (filing date: 2020-02-12), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Product sales ÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= 24,240 ÷ 5,297 = 4.58

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Amgen Inc.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.

Total Asset Turnover

Amgen Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Product sales 24,240  22,204  22,533  21,795  21,892 
Total assets 62,948  59,707  66,416  79,954  77,626 
Long-term Activity Ratio
Total asset turnover1 0.39 0.37 0.34 0.27 0.28
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.30 0.37 0.55 0.40 0.39
Eli Lilly & Co. 0.53 0.57 0.56 0.51 0.55
Gilead Sciences Inc. 0.36 0.36 0.34 0.37 0.53
Illumina Inc. 0.43 0.48 0.48 0.52 0.56
Johnson & Johnson 0.47 0.52 0.53 0.49 0.51
Merck & Co. Inc. 0.52 0.55 0.51 0.46 0.42
Pfizer Inc. 0.27 0.31 0.34 0.31 0.31
Regeneron Pharmaceuticals Inc. 0.50 0.53 0.57 0.67 0.70
Thermo Fisher Scientific Inc. 0.47 0.44 0.43 0.37 0.40
Zoetis Inc. 0.49 0.54 0.54 0.62 0.64
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.40 0.43 0.45 0.40 0.41
Total Asset Turnover, Industry
Health Care 0.59 0.60 0.63 0.61 0.63

Based on: 10-K (filing date: 2021-02-09), 10-K (filing date: 2020-02-12), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 2020 Calculation
Total asset turnover = Product sales ÷ Total assets
= 24,240 ÷ 62,948 = 0.39

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Amgen Inc.’s total asset turnover ratio improved from 2018 to 2019 and from 2019 to 2020.

Equity Turnover

Amgen Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Product sales 24,240  22,204  22,533  21,795  21,892 
Stockholders’ equity 9,409  9,673  12,500  25,241  29,875 
Long-term Activity Ratio
Equity turnover1 2.58 2.30 1.80 0.86 0.73
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.50 5.54 5.53
Eli Lilly & Co. 4.35 8.56 2.50 1.97 1.52
Gilead Sciences Inc. 1.34 0.98 1.01 1.26 1.59
Illumina Inc. 0.69 0.77 0.89 1.00 1.09
Johnson & Johnson 1.31 1.38 1.37 1.27 1.02
Merck & Co. Inc. 1.90 1.81 1.58 1.17 0.99
Pfizer Inc. 0.66 0.82 0.85 0.74 0.89
Regeneron Pharmaceuticals Inc. 0.77 0.71 0.77 0.96 1.09
Thermo Fisher Scientific Inc. 0.93 0.86 0.88 0.82 0.85
Zoetis Inc. 1.77 2.31 2.67 3.00 3.29
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.36 1.45 1.40 1.14 1.10
Equity Turnover, Industry
Health Care 1.70 1.72 1.73 1.63 1.60

Based on: 10-K (filing date: 2021-02-09), 10-K (filing date: 2020-02-12), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14).

1 2020 Calculation
Equity turnover = Product sales ÷ Stockholders’ equity
= 24,240 ÷ 9,409 = 2.58

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Amgen Inc.’s equity turnover ratio improved from 2018 to 2019 and from 2019 to 2020.